Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?
TheFly reported on June 14 that MLYS presented new data evaluating the impact of lorundrostat on heart failure risk biomarkers.









